Aegle Therapeutics Corp. is a first in class, Phase 1/2a ready, biotechnology company isolating extracellular vesicles (“EVs”) from allogeneic bone marrow derived mesenchymal stem cells to treat severe dermatological conditions, including burns and epidermolysis bullosa (“EB”), a rare pediatric connective tissue disorder, and to prevent scarring. Aegle’s EV therapy, using its proprietary platform isolation technology, has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells. Aegle believes its therapy has the potential for functional regeneration and organization of complex tissue structures that can enhance healing, reduce scarring, minimize contraction and improve overall cosmesis.